Targacept, Inc.

Grayland Page Dobson

Gary Maurice Dull

William Scott Caldwell

Craig Harrison Miller

Merouane Bencherif

Jared Miller Wagner

Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.

3-pyridinyl compounds

Pyrimidinyl compounds for treatment of central nervous system disorders

Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound. Exemplary compounds include (E)-N-methyl-4-&lsqb;3-(5-benzyloxypyridin)yl&rsqb;-3-buten-1-amine, (E)-N-methyl-4-&lsqb;3-(5-phenoxypyridin)yl&rsqb;-3-buten-1-amine, (E)-N-methyl-4-&lsqb;3-(5-isopropoxypyridin)yl&rsqb;-3-buten-1-amine, (E)-N-methyl-4-&lsqb;3-(5-methoxymethylpyridin)yl&rsqb;-3-buten-1-amine, and (E)-N-methyl-4-&lsqb;3-(5-phenylpyridin)yl&rsqb;-3-buten-1-amine.

Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds

Pharmaceutical compositions incorporate compounds that affect cytokine production and/or secretion. Such compounds include aryl substituted olefinic amine compounds, pyridyloxylalkylamines and phenoxyalkylamines, and aryl substituted amine compounds, such as 3-aminophenyl amine compounds. Such pharmaceutical compositions can be used for treating a wide variety of conditions, diseases and disorders, and particularly those associated with dysfunction of cytokine production and/or secretion. Of particular interest are pharmaceutical compositions useful for preventing and treating conditions, diseases and disorders associated with undesirably high levels of cytokine production and/or secretion. Such pharmaceutical compositions are useful for treating the effects of inflammatory bowel disease, inflammation, arthritis, cachexia in neoplastics diseases or associated with AIDS, and autoimmune diseases.

Pharmaceutical compositions for inhibition of cytokine production and secretion

Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines, including pyridyloxylalkylamines and phenoxyalkylamines, such as (3-(3-pyridyloxy)propyl)methylamine and (3-(5-bromo(3-pyridyloxy))propyl)methylamine.

Growing community of inventors

Winston-Salem, NC, United States of America

Grayland Page Dobson